EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines

Ahmad Mousa iD, David-Dan Nguyen, Aly-Khan Lalani, Raj Satkunasivam, Khatereh Aminoltejari, Amanda Hird, Soumyajit Roy iD, Scott C Morgan iD, Shawn Malone iD, Andrea Kokorovic, Luke T Lavallée, Melissa Huynh und 7 weitere

Cancer · 2025-01 · 131 (1)

DOI: 10.1002/cncr.35606 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Cancer, online erschienen am 13.10.2024. Verfasst von Ahmad Mousa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Antagonists, Guideline Adherence, Bone Density. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tolmar Pharmaceutiques, Knight Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgen‐deprivation therapy (ADT) remains a cornerstone in treatment for patients with advanced prostate cancer. ADT is associated with several adverse effects, including osteoporosis, metabolic syndrome, and cardiovascular events, leading to guidelines recommending routine testing to monitor for these toxicities. There is a lack of data assessing adherence to these recommendations.

Methods

The authors conducted a retrospective cohort study using administrative data from Ontario, Canada between 2008 and 2021. They identified all older men (aged 65 years and older) who received ADT for prostate cancer using comprehensive provincial health databases. The primary outcomes were the use of testing for lipids, dysglycemia (glucose), bone health serum, and bone density between 6 weeks before and 1 year after the initiation of ADT.

Results

In total, 29,097 patients were examined, of whom 52.8% were prescribed ADT by urologists, 37.9% were prescribed ADT by radiation oncologists, 2.8% were prescribed ADT by medical oncologists, and 2.4% were prescribed ADT by other physicians. Adherence to guidelines was low: only 21.3% of patients received a bone density scan, 41.2% underwent bone health–related serum tests, 51.3% completed a lipid profile, and 65.9% underwent dysglycemia testing within 1 year of diagnosis. Overall, only 11.9% of patients received all of the recommended investigations. Adherence to testing did not appear to improve over time (2008–2021) or with guideline publication. Patient (age) and physician (specialty) factors had important associations with adherence to testing.

Conclusions

Most patients receiving ADT for prostate cancer do not receive recommended testing to monitor for treatment‐related toxicity. Further study is required to address barriers to therapeutic monitoring of men on ADT and to reduce treatment‐associated adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen AntagonistsGuideline AdherenceBone DensityHumansMaleAgedRetrospective StudiesAged, 80 and overOntarioOsteoporosisAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

androgen‐deprivation therapybone mineral densitydysglycemiadyslipidemia, hypogonadismprostate cancer

Substanzen

Androgen AntagonistsAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medical Oncology, Juravinski Cancer Center, McMaster University, Hamilton, Ontario, Canada.
  • Department of Urology, Houston Methodist Hospital, Houston, Texas, USA.
  • Division of Urology, Department of Surgery, Princess Margaret Cancer Center, University of Toronto, Toronto, Ontario, Canada.
  • Division of Urology, Department of Surgery, Sunnybrook Health Sciences, University of Toronto, Toronto, Ontario, Canada.
  • Department of Radiation Oncology, Rush University Medical Center, Chicago, Illinois, USA.

ORCID-Profile: Ahmad Mousa, Soumyajit Roy, Scott C Morgan, Shawn Malone, Di Maria Jiang, Christopher J D Wallis

Förderung

  • Tolmar Pharmaceutiques
  • Knight Therapeutics

Zitieren

APA

Mousa, A., Nguyen, D. D., Lalani, A. K., Satkunasivam, R., Aminoltejari, K., Hird, A., Roy, S., Morgan, S. C., Malone, S., Kokorovic, A., Lavallée, L. T., Huynh, M., Shayegan, B., Jiang, D. M., Gotto, G., Breau, R. H., Kulkarni, G. S., Zlotta, A., & Wallis, C. J. D. (2025). Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines. Cancer, 131(1). https://doi.org/10.1002/cncr.35606

Vancouver

Mousa A, Nguyen DD, Lalani AK, Satkunasivam R, Aminoltejari K, Hird A, et al. Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines. Cancer. 2025;131(1). doi:10.1002/cncr.35606

BibTeX
@article{Mousa2025,
  author = {Mousa, Ahmad and Nguyen, David-Dan and Lalani, Aly-Khan and Satkunasivam, Raj and Aminoltejari, Khatereh and Hird, Amanda and Roy, Soumyajit and Morgan, Scott C and Malone, Shawn and Kokorovic, Andrea and Lavallée, Luke T and Huynh, Melissa and Shayegan, Bobby and Jiang, Di Maria and Gotto, Geofrey and Breau, Rodney H and Kulkarni, Girish S and Zlotta, Alexandre and Wallis, Christopher J D},
  title = {Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen‐deprivation therapy: A population‐based assessment of adherence to therapeutic monitoring guidelines},
  journal = {Cancer},
  year = {2025},
  volume = {131},
  number = {1},
  doi = {10.1002/cncr.35606}
}
Kostenlos starten →